May 11, 2026 04:23PM
Mar 31, 2026 07:06AM
Mar 31, 2026 06:40AM
Mar 31, 2026 06:40AM
Mar 4, 2026 04:20PM
Feb 26, 2026 08:23AM
Feb 26, 2026 08:23AM SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
Jan 28, 2026 08:00AM
Jan 21, 2026 08:01AM
Jan 21, 2026 08:00AM
Dec 22, 2025 08:02AM
Dec 22, 2025 08:00AM
Nov 19, 2025 07:00AM
Nov 17, 2025 10:16AM SCYNEXIS receives $7 million annual federal grant for antifungal research
Nov 17, 2025 10:15AM
Nov 5, 2025 04:20PM
Oct 28, 2025 07:14AM
Oct 15, 2025 08:01AM
Oct 15, 2025 08:00AM
Sep 30, 2025 08:00AM
Sep 30, 2025 08:00AM SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
Sep 4, 2025 08:30AM
Aug 25, 2025 08:00AM
Aug 13, 2025 04:30PM
May 28, 2025 08:31AM
May 28, 2025 08:30AM
May 15, 2025 04:20PM
Apr 8, 2025 08:05AM Scynexis (SCYX) to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases
Apr 8, 2025 08:00AM
Mar 12, 2025 05:08PM
Dec 18, 2024 08:00AM
Nov 6, 2024 04:30PM
Oct 10, 2024 08:00AM
Oct 3, 2024 08:00AM
Aug 27, 2024 08:00AM SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Aug 8, 2024 04:30PM
Jul 23, 2024 07:02AM
Jul 23, 2024 07:00AM
May 8, 2024 04:30PM
Apr 30, 2024 04:05PM
Apr 9, 2024 04:05PM
Mar 28, 2024 04:01PM SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
Jan 30, 2024 04:05PM
Jan 29, 2024 05:15PM
Jan 29, 2024 05:15PM
Jan 5, 2024 09:00PM
Jan 5, 2024 09:45AM
Jan 5, 2024 08:30AM
Jan 2, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SCYNEXIS, Li-Cycle, and FMC and Encourages Investors to Contact the Firm
Dec 28, 2023 09:00PM

323,580 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All